OticPharma Appoints Keith Katkin Chair
This article was originally published in Scrip
OticPharma Ltd., a privately held specialty pharmaceutical company focused on acquiring and developing innovative therapies for ear, nose, and throat disorders, has named Keith A. Katkin chair of its board of directors. Katkin is currently president CEO and a member of the board of directors of Avanir Pharmaceuticals. Prior to joining Avanir, he was vice president of commercial development for Peninsula Pharmaceuticals, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson.